We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back to Poster-Presentations-Details

T-36: Precision Enrollment in Oncology: Accelerating Start-up and Recruitment





Poster Presenter

      Rod Walker

      • Operations Lead, Quintiles Precision Enrollment
      • QuintilesIMS
        United States

Objectives

Participants reading this poster will learn about the challenges facing the precision medicine field and how QuintilesIMS uses technology and site networks to significantly accelerate patient recruitment and site startup in oncology precision medicine trials.

Method

The study was conducted in the NA and EU, in 1st line treatment to extend the product line. We were able to partner with sites in our network to meet recruitment timelines by utilizing master agreements and central institutional review board.

Results

In this poster, Rod Walker will explain how the development of a precision enrollment model is addressing these challenges. The poster will outline best practices for developing a site network and new approaches to patient recruitment and site startup for precision medicine studies. Additionally, a case study will be shared to demonstrate how this program has successfully activated a site –after a patient has been identified – within 12 days for a phase III renal cell carcinoma trial.

Conclusion

This topic is relevant to a variety of stakeholders at DIA. For sites and investigators, the poster will explain how this precision enrollment program can help accelerate patient enrollment and site activation. For sponsors, it will share how we are reversing the traditional paradigm of opening sites and then finding patients to speed the time it takes to get new treatments to market. Most importantly, the poster will highlight how patients are benefitting from this innovative program. Through the use of this process, more patients will have access to more trials without having to travel to distant oncology centers to take advantage of new treatments.